Multiple sclerosis treatment works on three fronts: slowing the disease itself with long-term medications, treating flare-ups when they happen, and managing the day-to-day symptoms that affect quality of life. There is no cure for MS, but the number of effective treatments has grown dramatically over the past two decades. More than 20 disease-modifying therapies are now approved, and the newest options can reduce relapses by as much as 70% compared to no treatment.
Disease-Modifying Therapies
Disease-modifying therapies, or DMTs, are the backbone of MS treatment. Their job is to calm the immune system’s attack on the protective coating around nerve fibers in the brain and spinal cord. By doing this, they reduce the number of relapses, slow the accumulation of disability, and limit new areas of damage visible on MRI scans. Most people with relapsing forms of MS start a DMT shortly after diagnosis.
These medications come in three forms: self-injections, pills, and infusions given at a clinic. The choice depends on how active your disease is, your tolerance for risk, and what fits your life practically.
Self-Injected Medications
The earliest MS drugs were interferons, which are synthetic versions of proteins your body already makes to regulate immune responses. Several interferon formulations are still available and given by injection anywhere from every other day to every two weeks, depending on the specific product. Another long-standing injectable, glatiramer acetate, works differently by redirecting certain immune cells away from attacking nerve tissue. These older injectables tend to have well-understood safety profiles after decades of use, but they are generally less potent than newer options. A newer self-injection, ofatumumab, is far more powerful. It targets a protein called CD20 on the surface of B cells (a type of immune cell heavily involved in MS) and eliminates them from circulation. You give it monthly at home with a pen-style device after an initial loading period.
Oral Medications
Pills became available for MS starting around 2010 and changed the treatment landscape. Several categories exist. One group works by trapping certain immune cells inside lymph nodes so they can’t travel to the brain and cause damage. Another group reduces inflammation through pathways that also appear to protect nerve cells. A third, cladribine, takes a different approach: you take short courses of pills over two years, and the treatment resets parts of your immune system for years afterward, with no daily medication in between. Across large clinical trials, approved oral DMTs reduced annual relapse rates by roughly 50 to 70% compared to placebo.
Infusion Therapies
Infusions are typically the most potent options and are often reserved for people with highly active disease or those who haven’t responded well to other treatments. Ocrelizumab, given every six months, targets the same CD20 protein on B cells as ofatumumab and has shown strong results in both relapsing and primary progressive MS. Ublituximab works through a similar mechanism with a one-hour infusion. Natalizumab blocks immune cells from crossing the blood-brain barrier into the central nervous system and is one of the most effective therapies available, though it carries a rare but serious risk of a brain infection that requires regular monitoring. Alemtuzumab is given in two short courses a year apart and can produce lasting remission, but it requires years of follow-up blood work because it can trigger other autoimmune conditions.
These B-cell-depleting therapies work by binding to CD20 on the cell surface and triggering several killing mechanisms: they can signal the body’s complement system to destroy the cell, recruit natural killer cells to attack it, or cause the cell to self-destruct. The result is a sharp drop in circulating B cells, which substantially reduces new inflammatory activity in the brain.
How Relapses Are Treated
Even on a DMT, some people experience relapses, which are new or worsening neurological symptoms lasting at least 24 hours. Not every relapse needs treatment. Mild sensory symptoms like tingling that don’t interfere with function sometimes resolve on their own within weeks. But relapses that affect vision, walking, or strength are typically treated with high-dose corticosteroids to shorten the episode and speed recovery.
The standard approach is intravenous methylprednisolone given daily for three to five days. High-dose oral steroids have been shown to be equally effective, with a specific oral dose matching the bioavailability of the IV version. This means some relapses can be treated at home rather than at an infusion center, which many people prefer. Steroids don’t change the long-term course of MS, but they reduce inflammation quickly and help you get back to baseline faster.
For relapses that don’t respond to steroids, plasma exchange is a second-line option. This procedure filters the blood to remove the antibodies and inflammatory proteins driving the attack. The American Academy of Neurology recommends it specifically for steroid-resistant relapses in relapsing forms of MS.
Symptom Management
MS can produce a wide range of symptoms beyond relapses, and these often need their own treatment strategies. The most common issues include fatigue, muscle stiffness (spasticity), bladder problems, pain, and difficulty with balance or walking.
Fatigue is the single most reported symptom. It’s not ordinary tiredness; it’s a heavy, overwhelming exhaustion that can hit even after a full night’s sleep. Management usually combines energy conservation strategies (planning rest periods, prioritizing tasks, keeping cool) with exercise, which counterintuitively tends to improve MS fatigue rather than worsen it. Some people also benefit from medications that promote wakefulness.
Spasticity, or abnormal muscle tightness, responds to stretching, physical therapy, and oral muscle relaxants. When stiffness is severe and localized, injections that block nerve signals to the affected muscles can provide months of relief. Bladder dysfunction is extremely common and ranges from urgency and frequency to difficulty emptying the bladder completely. Pelvic floor physical therapy, timed voiding schedules, and medications that calm overactive bladder muscles are all part of the toolkit.
Pain in MS takes many forms. Nerve pain, which feels like burning, stabbing, or electric shocks, is treated with medications originally developed for seizures or depression that quiet overactive nerve signals. Musculoskeletal pain from altered gait or posture responds better to physical therapy and conventional pain relief.
Rehabilitation and Exercise
Rehabilitation is not a one-time event after a relapse. It’s an ongoing part of MS care. Physical therapy focused on strength, balance, and flexibility helps maintain mobility and prevent falls. Occupational therapy addresses fine motor skills and teaches adaptive techniques for daily tasks that become harder as the disease progresses.
Cognitive rehabilitation has gained strong support in recent years. About half of people with MS experience some degree of cognitive change, most commonly with processing speed, memory, and multitasking. Structured cognitive training can enhance neuroplasticity, meaning the brain builds new connections to compensate for damaged ones. The benefits extend beyond thinking skills: studies show cognitive rehabilitation also improves fatigue, mood, and overall quality of life.
One particularly promising approach is dual-task training, where you practice cognitive challenges while simultaneously walking or doing physical exercises. A four-week program of walking on a treadmill while performing cognitive tasks significantly improved both gait endurance and mobility compared to muscle training alone. These gains make sense given that real life constantly demands doing two things at once, like walking while carrying on a conversation, which is exactly the kind of situation that becomes difficult with MS.
Vitamin D and Lifestyle Factors
Low vitamin D levels are consistently linked to higher MS risk and more active disease. Most neurologists check vitamin D levels and recommend supplementation if they’re low. In clinical studies, high-dose supplementation has ranged widely, from about 2,800 to over 20,000 IU per day, but the optimal dose and target blood level for MS specifically remain unclear. What is clear is that letting levels stay low is not ideal, and most MS specialists aim to keep patients in the upper end of the normal range.
Smoking worsens MS outcomes across the board: faster disability progression, more brain atrophy, and poorer response to treatment. Quitting is one of the most impactful lifestyle changes you can make. Regular aerobic exercise, maintained over time, has been shown to improve walking speed, reduce fatigue, and may even have a modest protective effect on brain volume. A balanced diet rich in fruits, vegetables, and omega-3 fatty acids is generally recommended, though no specific diet has been proven to alter the disease course.
Newer Therapies on the Horizon
The next generation of MS treatments aims to go beyond suppressing the immune system in the blood. A class of drugs called BTK inhibitors can cross into the brain and target immune cells that live there permanently, called microglia. These resident brain immune cells have been linked to the slow, smoldering inflammation that drives progressive disability even when relapses are controlled.
Fenebrutinib, the most advanced of these drugs, has met its primary goals in three large Phase III trials. In a study of 746 people with relapsing MS, it significantly reduced annual relapse rates compared to an established oral therapy over at least 96 weeks. Notably, it also met its endpoint in a trial of 985 people with primary progressive MS, a form of the disease that currently has very few treatment options. If approved, it would represent a meaningful shift in how progressive MS is treated, addressing inflammation inside the brain rather than just in the bloodstream.